A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY
Clinical trial NCT05735327 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05735327
- Sponsor
- Takeda
- Status
- ACTIVE_NOT_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2023-05-22
- Primary completion
- 2027-04-26
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.